Literature DB >> 29969320

Procalcitonin-guided antibiotic therapy algorithms for different types of acute respiratory infections based on previous trials.

Philipp Schuetz1,2, Rebekka Bolliger2, Meret Merker2, Mirjam Christ-Crain1,3, Daiana Stolz1,4, Michael Tamm1,4, Charles E Luyt5, Michel Wolff6, Stefan Schroeder7, Vandack Nobre8, Konrad Reinhart9, Angela Branche10, Pierre Damas11, Maarten Nijsten12, Rodrigo O Deliberato13, Alessia Verduri14, Bianca Beghé14, Bin Cao15, Yahya Shehabi16,17, Jens-Ulrik S Jensen18,19, Albertus Beishuizen20, Evelien de Jong21, Matthias Briel1,22, Tobias Welte23, Beat Mueller1,2.   

Abstract

INTRODUCTION: Although evidence indicates that use of procalcitonin to guide antibiotic decisions for the treatment of acute respiratory infections (ARI) decreases antibiotic consumption and improves clinical outcomes, algorithms used within studies had differences in PCT cut-off points and frequency of testing. We therefore analyzed studies evaluating procalcitonin-guided antibiotic therapy and propose consensus algorithms for different respiratory infection types. Areas covered: We systematically searched randomized-controlled trials (search strategy updated on February 2018) on procalcitonin-guided antibiotic therapy of ARI in adults using a pre-specified Cochrane protocol and analyzed algorithms from 32 trials that included 10,285 patients treated in primary care settings, emergency departments (ED), and intensive care units (ICU). We derived consensus algorithms for use of procalcitonin by the type of ARI including community-acquired pneumonia, bronchitis, chronic obstructive pulmonary disease or asthma exacerbation, sepsis, and post-operative sepsis due to respiratory infection. Consensus algorithm recommendations differ with regard to timing of treatment (i.e. timing of initiation in low-risk patients or discontinuation in high-risk patients) and procalcitonin cut-off points for the recommendation/strong recommendation to discontinue antibiotics (≤ 0.25/≤ 0.1 µg/L in ED and inpatients, ≤ 0.5/≤ 0.25 µg/L in ICU patients, and reduction by ≥ 80% from peak levels in sepsis patients). Expert commentary: Our proposed algorithms may facilitate safe and efficient implementation of procalcitonin-guided antibiotic protocols in diverse healthcare settings. Still, the decision about initiation and cessation of antibiotic treatment remains a clinical decision based on the patient assessment and the severity of illness and use of procalcitonin should not delay empirical treatment in high risk situations.

Entities:  

Keywords:  Procalcitonin; antibiotic stewardship; pneumonia; respiratory infection; systematic review

Mesh:

Substances:

Year:  2018        PMID: 29969320     DOI: 10.1080/14787210.2018.1496331

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN: 1478-7210            Impact factor:   5.091


  9 in total

Review 1.  [S2k guidelines of the PEG on calculated parenteral initial treatment of bacterial diseases in adults : Focussed summary and supplementary information on antibiotic treatment of critically ill patients].

Authors:  A Brinkmann; A C Röhr; O R Frey; W A Krüger; T Brenner; D C Richter; K-F Bodmann; M Kresken; B Grabein
Journal:  Anaesthesist       Date:  2018-12       Impact factor: 1.041

2.  A Haemophilus sp. dominates the microbiota of sputum from UK adults with non-severe community acquired pneumonia and chronic lung disease.

Authors:  Daniel G Wootton; Michael J Cox; Gregory B Gloor; David Litt; Katja Hoschler; Esther German; Joanne Court; Odiri Eneje; Lynne Keogan; Laura Macfarlane; Sarah Wilks; Peter J Diggle; Mark Woodhead; Miriam F Moffatt; William O C Cookson; Stephen B Gordon
Journal:  Sci Rep       Date:  2019-02-20       Impact factor: 4.379

3.  Clinical Significance of Procalcitonin, C-Reactive Protein, and Interleukin-6 in Helping Guide the Antibiotic Use for Patients with Acute Exacerbations of Chronic Obstructive Pulmonary Disease.

Authors:  Wen Song; Yue Wang; Fengming Tian; Liang Ge; Xiaoqian Shang; Qiang Zeng; Ning Feng; Jiahui Fan; Jing Wang; Xiumin Ma
Journal:  Dis Markers       Date:  2021-03-15       Impact factor: 3.434

4.  Procalcitonin as a biomarker of bacterial infection in critically ill patients admitted with suspected Sepsis in Intensive Care Unit of a tertiary care hospital.

Authors:  Afshan Bibi; Nida Basharat; Muhammad Aamir; Zujaja Hina Haroon
Journal:  Pak J Med Sci       Date:  2021 Nov-Dec       Impact factor: 1.088

5.  Stemming the Rise of Antibiotic Use for Community-Acquired Acute Respiratory Infections during COVID-19 Pandemic.

Authors:  Shena Y C Lim; Yvonne P Zhou; Daphne Yii; De Zhi Chin; Kai Chee Hung; Lai Wei Lee; Jia Le Lim; Li Wen Loo; Narendran Koomanan; Nathalie Grace Chua; Yixin Liew; Benjamin P Z Cherng; Siew Yee Thien; Winnie H L Lee; Andrea L H Kwa; Shimin J Chung
Journal:  Antibiotics (Basel)       Date:  2022-06-24

6.  Association of Antibiotic Treatment With Outcomes in Patients Hospitalized for an Asthma Exacerbation Treated With Systemic Corticosteroids.

Authors:  Mihaela S Stefan; Meng-Shiou Shieh; Kerry A Spitzer; Penelope S Pekow; Jerry A Krishnan; David H Au; Peter K Lindenauer
Journal:  JAMA Intern Med       Date:  2019-03-01       Impact factor: 21.873

Review 7.  Biomarkers of Infection: Are They Useful in the ICU?

Authors:  Eva Heilmann; Claudia Gregoriano; Philipp Schuetz
Journal:  Semin Respir Crit Care Med       Date:  2019-10-04       Impact factor: 3.119

8.  Duration of antibiotic treatment using procalcitonin-guided treatment algorithms in older patients: a patient-level meta-analysis from randomized controlled trials.

Authors:  Eva Heilmann; Claudia Gregoriano; Djillali Annane; Konrad Reinhart; Lila Bouadma; Michel Wolff; Jean Chastre; Charles-Edouard Luyt; Florence Tubach; Angela R Branche; Matthias Briel; Mirjam Christ-Crain; Tobias Welte; Caspar Corti; Evelien de Jong; Maarten Nijsten; Dylan W de Lange; Jos A H van Oers; Albertus Beishuizen; Armand R J Girbes; Rodrigo O Deliberato; Stefan Schroeder; Kristina B Kristoffersen; Nathalie Layios; Pierre Damas; Stella S S Lima; Vandack Nobre; Long Wei; Carolina F Oliveira; Yahya Shehabi; Daiana Stolz; Michael Tamm; Alessia Verduri; Jin-Xiang Wang; Sabine Drevet; Gaetan Gavazzi; Beat Mueller; Philipp Schuetz
Journal:  Age Ageing       Date:  2021-09-11       Impact factor: 10.668

9.  Correlation between LRP1B Mutations and Tumor Mutation Burden in Gastric Cancer.

Authors:  Sizhe Hu; Xiaokang Zhao; Feng Qian; Cancan Jin; Kaishun Hou
Journal:  Comput Math Methods Med       Date:  2021-09-21       Impact factor: 2.238

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.